All Comments by Michael G. Agadjanyan
Go to another page:
- 1
- 2
- Alzheimer disease neuropathology in a patient previously treated with aducanumab.
- Anti-Tau Antibody Data Leave Best Isotype Unclear
- Dale Schenk, 59, Pioneer of Alzheimer’s Immunotherapy
- Bapineuzumab Phase 3: Target Engagement, But No Benefit
- Smuggling Antibodies to BACE Across the Blood-Brain Barrier
- DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
- DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
- Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice.
- Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.
- Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
- A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta.
- Immunotherapy Update: Toward Patches and Creams
- Aβ Star is Born? Memory Loss in APP Mice Blamed on Oligomer
- Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety.
- Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.